Charles river and inadcure announce gene therapy manufacturing collaboration

Alderley park, england--(business wire)--charles river laboratories international, inc. (nyse: crl) and the inadcure foundation, a nonprofit organization whose mission is to support the development of treatments for infantile neuroaxonal dystrophy (inad) and other forms of pla2g6-related neurodegeneration (plan), today announced a plasmid dna manufacturing alliance. the collaboration will leverage charles river's market leading contract development and manufacturing organization (cdmo) expertis.
CRL Ratings Summary
CRL Quant Ranking